News

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

Siegfried Priglinger, MD discussed research he presented focused on pediatric patients with inherited retinal diseases with an emphasis on studies into the RPE65 gene.

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of the cornea.

Mark Daly discusses the transformative role of AI in ophthalmology, highlighting its potential to enhance patient care and streamline physician workflows.

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and treatment through advanced imaging technology.

The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future treatments.

On the heels of its FDA approval, clinicians weigh in on acoltremon’s (Tryptry) novel mechanism of action and its potential to address unmet needs in dry eye care

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, showcasing significant visual acuity improvements.

Researchers share that perfluorohexylactane eye drops offer rapid relief for dry eye disease, enhancing patient comfort before cataract surgery.

The preservative-free, contact lens-friendly drops have been formulated to provide hydration and comfort for dry eyes in a multi-dose bottle.

A study reveals attrition rates in geographic atrophy patients on complement inhibitor therapies, highlighting the need for improved treatment compliance strategies.

Centennial Optical distributes ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories.

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, offering reduced risks and improved outcomes.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

Areas covered by the agreement would cover key Asian marketplaces, including Japan and China.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term patient care.

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and surgery options.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026.

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President Donald Trump under the International Emergency Economic Powers Act.

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a significant advancement in treatment.

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term glaucoma management.

Discover how ellipsoid zone integrity predicts geographic atrophy growth rates in recent clinical trials, enhancing future treatment strategies.

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.